Clinical Trials · NCT02914665
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 308
- Start date
- Oct 2016
- Locations
- 46 sites, 10 countries
- Primary endpoint
- Change in NT-proBNP between Baseline and Day 8/Early Discharge